Sood Harpreet S, Cox Michael J, Tyagi Suresh C
Department of Physiology and Biophysics, School of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Antioxid Redox Signal. 2002 Oct;4(5):799-804. doi: 10.1089/152308602760598954.
The hypothesis is that homocysteine decreases endothelial nitric oxide (NO) availability by generating nitrotyrosine. In the absence of NO, and in an attempt to reduce endocardial load by dilatation, the matrix metalloproteinase (MMP) is activated. To address this hypothesis, homocysteine (0.67 mg/ml) was administered in drinking water of Sprague-Dawley rats for 8 weeks. To elicit the reversible effects of homocysteine, homocysteine was removed from the water after 8 weeks. The plasma levels of homocysteine were 2.79 +/- 0.5 microM in control (n = 6), measured by spectrofluorometry. The levels of homocysteine increased to 22 +/- 1.3 and 17 +/- 2.8 microM following 4 (n = 6) and 8 (n = 6) weeks of homocysteine treatment, respectively. The level of homocysteine decreased to 5.8 +/- 1.0 microM (n = 6) when homocysteine was removed from the drinking water. The mean arterial pressure (MAP) of control rats was 108 +/- 10 mm Hg and increased to 128 +/- 2 and 130 +/- 3 mm Hg following 4 and 8 weeks of homocysteine treatment, respectively. When homocysteine was removed from the drinking water, the MAP was decreased to 118 +/- 3 mm Hg. Left ventricle (LV) parameters were measured by a catheter in the LV through right common carotid artery in anesthetized rats. The LV tissue was analyzed for MMP activity by zymography. Levels of nitrotyrosine and cardiospecific tissue inhibitor of metalloproteinase-4 (TIMP-4/CIMP) were measured by western blot analysis using the respective antibodies. The specific bands in zymographic gel and western blot were scanned and normalized with beta-actin. The results suggest a continuous increase in nitrotyrosine levels at 4 and 8 weeks after homocysteine administration. The removal of homocysteine did not decrease the levels of nitrotyrosine. The zymographic analysis revealed a temporal increase in MMP-2 activity from 4 to 8 weeks post homocysteine administration. However, removal of homocysteine did not decrease the MMP-2 activity. The cardiac active diastolic function, -dP/dt, was decreased at 4 weeks and stayed depressed up to 12 weeks. The end-diastolic pressure started increasing at 8 weeks; at this point the MMP-2 activity was also increased. The results suggest that in the absence of endothelial NO, and in an attempt to reduce LV load, MMP-2 is activated and CIMP is inactivated, by increasing nitrotyrosine.
该假说认为,同型半胱氨酸通过生成硝基酪氨酸降低内皮型一氧化氮(NO)的可用性。在缺乏NO的情况下,为了通过扩张来减轻心内膜负荷,基质金属蛋白酶(MMP)被激活。为了验证这一假说,将同型半胱氨酸(0.67 mg/ml)添加到Sprague-Dawley大鼠的饮用水中,持续8周。为了引发同型半胱氨酸的可逆效应,8周后将同型半胱氨酸从水中去除。通过荧光分光光度法测定,对照组(n = 6)的血浆同型半胱氨酸水平为2.79±0.5 microM。同型半胱氨酸处理4周(n = 6)和8周(n = 6)后,同型半胱氨酸水平分别升至22±1.3 microM和17±2.8 microM。当从饮用水中去除同型半胱氨酸后,同型半胱氨酸水平降至5.8±1.0 microM(n = 6)。对照组大鼠的平均动脉压(MAP)为108±10 mmHg,同型半胱氨酸处理4周和8周后分别升至128±2 mmHg和130±3 mmHg。当从饮用水中去除同型半胱氨酸后,MAP降至118±3 mmHg。在麻醉大鼠中,通过右颈总动脉将导管插入左心室(LV)来测量LV参数。通过酶谱法分析LV组织中的MMP活性。使用相应抗体通过蛋白质印迹分析测定硝基酪氨酸和心脏特异性金属蛋白酶组织抑制剂-4(TIMP-4/CIMP)的水平。对酶谱凝胶和蛋白质印迹中的特异性条带进行扫描,并用β-肌动蛋白进行标准化。结果表明,同型半胱氨酸给药后4周和8周,硝基酪氨酸水平持续升高。去除同型半胱氨酸并未降低硝基酪氨酸水平。酶谱分析显示,同型半胱氨酸给药后4至8周,MMP-2活性随时间增加。然而,去除同型半胱氨酸并未降低MMP-2活性。心脏主动舒张功能-dP/dt在4周时降低,并持续至12周仍处于抑制状态。舒张末期压力在8周时开始升高;此时MMP-2活性也增加。结果表明,在缺乏内皮型NO的情况下,为了减轻LV负荷,MMP-2被激活,而CIMP因硝基酪氨酸增加而失活。